CONTEXT - The European Association of Urology (EAU) guidelines panel on upper urinary tract urothelial cell carcinoma (UTUC) has prepared updated guidelines to aid clinicians in the current evidence-based management of UTUC and to incorporate recommendations into clinical practice.
OBJECTIVES - To provide a brief overview of the EAU guidelines on UTUC as an aid to clinicians.
EVIDENCE AQUISITION - The recommendations provided in the current guidelines are based on a thorough review of available UTUC guidelines and articles identified following a systematic search of Medline. Data on urothelial malignancies and UTUC were searched using these keywords: urinary tract cancer; urothelial carcinomas; upper urinary tract, carcinoma; renal pelvis; ureter; bladder cancer; chemotherapy; nephroureterectomy; adjuvant treatment; instillation; neoadjuvant treatment; recurrence; risk factors; and survival. References were weighted by a panel of experts.
EVIDENCE SYNTHESIS - Due to the rarity of UTUC, there are insufficient data to provide strong recommendations (ie, grade A). However, the results of recent multicentre studies are now available, and there is a growing interest in UTUC. The 2009 TNM classification is recommended. Recommendations are given for diagnosis and risk stratification as well as radical and conservative treatment, and prognostic factors are discussed. A single postoperative dose of intravesical mitomycin after nephroureterectomy reduces the risk of bladder tumour recurrence. Recommendations are also provided for patient follow-up after different therapeutic strategies.
CONCLUSIONS - These guidelines contain information on the management of individual patients according to a current standardised approach. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen, based on the proposed risk stratification of these tumours.
PATIENT SUMMARY - Urothelial carcinoma of the upper urinary tract is rare, but because 60% of these tumours are invasive at diagnosis, an appropriate diagnosis is most important. A number of known risk factors exist.
Eur Urol. 2015 Jul 15. pii: S0302-2838(15)00550-3. doi: 10.1016/j.eururo.2015.06.044. [Epub ahead of print]
Rouprêt M1, Babjuk M2, Compérat E3, Zigeuner R4, Sylvester RJ5, Burger M6, Cowan NC7, Böhle A8, Van Rhijn BW9, Kaasinen E10, Palou J11, Shariat SF12.
1 Department of Urology, Hospital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, University Pierre et Marie Curie, Institut Universitaire de Cancérologie, Paris, France.
2 Department of Urology, Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.
3 Department of Pathology, Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, University Pierre et Marie Curie, Institut Universitaire de Cancérologie, Paris, France.
4 Department of Urology, Medizinische Universität Graz, Graz, Austria.
5 EAU Guidelines Office Board, European Association of Urology, The Netherlands.
6 Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany.
7 Department of Radiology, Queen Alexandra Hospital, Portsmouth, UK.
8 Helios Agnes Karll Krankenhaus, Schwartau, Germany.
9 Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
10 Department of Surgery, Hyvinkää Hospital, Hyvinkää, Finland.
11 Department of Urology, Universitat Autònoma de Barcelona-Fundació Puigvert, Barcelona, Spain.
12 Department of Urology, Comprehensive Cancer Centre, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Department of Urology, Weill Medical College of Cornell University, New York, NY, USA; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.